Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 21

Trial Status

Terminated1
Other1

Role Distribution

Principal Investigator2
PI Rate100%

Activity Timeline

Clinical Trials (2)

NCT01859689Phase 2Withdrawn
Internal Radiation Therapy in Treating Patients With Low-Risk Prostate Cancer
Adenocarcinoma of the ProstateRecurrent Prostate CancerStage I Prostate Cancer+2 more
Principalinvestigator
NCT02336763Not ApplicableTerminated
Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases
Iris MelanomaMedium/Large Size Posterior Uveal MelanomaStage IIA Uveal Melanoma+4 more
Principalinvestigator

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Stephen Michael Hahn

Abramson Cancer Center at Penn Medicine

Related
6 trials

Shared therapeutic areas:

Adenocarcinoma of the ProstateRecurrent Prostate CancerStage I Prostate Cancer+2 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score13%

Ulka Vaishampayan

Barbara Ann Karmanos Cancer Institute

Related
4 trials

Shared therapeutic areas:

Adenocarcinoma of the ProstateRecurrent Prostate CancerStage I Prostate Cancer+2 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score13%

Sagus Sampath

City of Hope Medical Center

Related
3 trials

Shared therapeutic areas:

Recurrent Prostate CancerStage I Prostate CancerStage IIA Prostate Cancer+1 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score10%

Tanya Dorff

University of Southern California

Related
3 trials

Shared therapeutic areas:

Adenocarcinoma of the ProstateRecurrent Prostate CancerStage IIA Prostate Cancer+1 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score10%

Jacek Pinski

University of Southern California

Related
4 trials

Shared therapeutic areas:

Recurrent Prostate CancerStage I Prostate CancerStage IIA Prostate Cancer+1 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score10%

David I Quinn, MD

University of Southern California

Related
3 trials

Shared therapeutic areas:

Stage I Prostate CancerStage IIA Prostate CancerStage IIB Prostate Cancer

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score8%

Ellis Levine, MD

Roswell Park Cancer Institute

Related
4 trials

Shared therapeutic areas:

Stage I Prostate CancerStage IIA Prostate CancerStage IIB Prostate Cancer

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score8%

Robert Montgomery

Fred Hutch/University of Washington Cancer Consortium

Related
6 trials

Shared therapeutic areas:

Stage IIA Prostate CancerStage IIB Prostate Cancer

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score5%

Stanislaw R. Burzynski, MD, PhD

Burzynski Research Institute

Related
62 trials

Shared therapeutic areas:

Adenocarcinoma of the ProstateRecurrent Prostate Cancer
Similarity Score5%

Mark N. Stein, MD

Columbia University

Related
4 trials

Shared therapeutic areas:

Recurrent Prostate CancerAdenocarcinoma of the Prostate
Similarity Score5%

Publications (0)

No publications found for this investigator.

Clinical Trials (2)

Showing 2 of 2 trials

NCT01859689Phase 2PrincipalInvestigator

Internal Radiation Therapy in Treating Patients With Low-Risk Prostate Cancer

Adenocarcinoma of the ProstateRecurrent Prostate CancerStage I Prostate Cancer+2 more
Withdrawn
NCT02336763Not ApplicablePrincipalInvestigator

Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases

Iris MelanomaMedium/Large Size Posterior Uveal MelanomaStage IIA Uveal Melanoma+4 more
Terminated

All 2 trials loaded